

How Saxenda works in your body explained in plain English. Learn about GLP-1, appetite regulation, and how it compares to Wegovy and Zepbound.
That's the short answer. Saxenda (Liraglutide) is a GLP-1 receptor agonist — a medication that copies the effects of a natural hormone in your body called GLP-1. By activating the same receptors that GLP-1 targets, Saxenda reduces hunger, helps you eat less, and supports weight loss.
But what does that actually mean inside your body? Let's break it down in plain language.
GLP-1 stands for glucagon-like peptide-1. It's a hormone produced in your small intestine after you eat. When food enters your gut, GLP-1 is released and does several important things:
The problem? Natural GLP-1 is broken down by your body very quickly — within minutes. Its effects are short-lived.
Saxenda's active ingredient, Liraglutide, is a modified version of human GLP-1. Scientists tweaked the molecular structure so that it resists the enzyme (DPP-4) that normally breaks down GLP-1. The result is a medication that activates the same receptors as natural GLP-1, but lasts much longer — about 13 hours in your body, compared to just a few minutes for the natural hormone.
This is why Saxenda is injected once daily. Each injection provides a sustained level of GLP-1 receptor activation throughout a large portion of the day.
Here's a step-by-step look at what happens in your body after you inject Saxenda:
Most people start noticing reduced appetite within the first week or two of treatment, even at the starting dose of 0.6 mg. However, meaningful weight loss takes longer.
In clinical trials, patients typically saw:
Your doctor will usually evaluate your progress at 16 weeks. If you haven't lost at least 4% of your body weight by that point, they may discuss whether to continue or try a different approach.
Keep in mind that the five-week dose escalation means you won't reach the full dose until week 5. This gradual ramp-up is designed to reduce side effects, especially nausea.
Each dose of Saxenda provides appetite-suppressing effects for most of the day. Liraglutide has a half-life of about 13 hours, meaning it stays active in your system for a good portion of each 24-hour period.
However, Saxenda's effects depend on continued use. If you stop taking it, the medication clears your system within a few days and your appetite will return to its pre-treatment level. This is why Saxenda is designed for long-term use as part of an ongoing weight management plan that includes diet and exercise.
Some patients experience weight regain after stopping Saxenda. This is normal and reflects the fact that obesity is a chronic condition — similar to how blood pressure rises again when you stop taking blood pressure medication.
Saxenda isn't the only GLP-1 medication for weight loss. Here's how it stacks up against the newer options:
Both are GLP-1 receptor agonists, but they're different medications:
Zepbound (Tirzepatide) is a newer type of medication — a dual GIP/GLP-1 receptor agonist:
Your doctor can help you decide which medication is best for your situation based on your health history, goals, insurance coverage, and what's available. For a deeper comparison, read our guide to alternatives to Saxenda.
Saxenda works by doing what your body already tries to do — signal your brain that you're full. The difference is that Saxenda's effects are stronger and longer-lasting than the natural hormone. Combined with a reduced-calorie diet and exercise, it can be an effective tool for sustained weight loss.
If you and your doctor decide Saxenda is right for you, Medfinder can help you find a pharmacy with it in stock. And if cost is a concern, check out our guide to Saxenda savings programs.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.